Immunofluorescence  ||| S:0 E:19 ||| JJ
expression  ||| S:19 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
Ki-67 ||| S:33 E:38 ||| NNP
,  ||| S:38 E:40 ||| ,
p53  ||| S:40 E:44 ||| NN
and  ||| S:44 E:48 ||| CC
cyclin  ||| S:48 E:55 ||| JJ
inhibitors  ||| S:55 E:66 ||| NNS
( ||| S:66 E:67 ||| -LRB-
p16ink4a ||| S:67 E:75 ||| NNP
,  ||| S:75 E:77 ||| ,
p21  ||| S:77 E:81 ||| NNP
and  ||| S:81 E:85 ||| CC
p27 ||| S:85 E:88 ||| CD
)  ||| S:88 E:90 ||| -RRB-
in  ||| S:90 E:93 ||| IN
low-grade  ||| S:93 E:103 ||| JJ
cervical  ||| S:103 E:112 ||| FW
lesions  ||| S:112 E:120 ||| FW
versus  ||| S:120 E:127 ||| FW
high-grade  ||| S:127 E:138 ||| FW
cervical  ||| S:138 E:147 ||| FW
lesions ||| S:147 E:154 ||| FW
.  ||| S:154 E:156 ||| .
Research  ||| S:156 E:165 ||| NNP
study  ||| S:165 E:171 ||| NN
on  ||| S:171 E:174 ||| IN
cell  ||| S:174 E:179 ||| NN
cultures  ||| S:179 E:188 ||| NNS
The  ||| S:188 E:192 ||| DT
aim  ||| S:192 E:196 ||| NN
of  ||| S:196 E:199 ||| IN
this  ||| S:199 E:204 ||| DT
research  ||| S:204 E:213 ||| NN
was  ||| S:213 E:217 ||| VBD
to  ||| S:217 E:220 ||| TO
assess  ||| S:220 E:227 ||| VB
the  ||| S:227 E:231 ||| DT
immunofluorescence  ||| S:231 E:250 ||| JJ
expression  ||| S:250 E:261 ||| NN
( ||| S:261 E:262 ||| -LRB-
IFE ||| S:262 E:265 ||| NNP
)  ||| S:265 E:267 ||| -RRB-
of  ||| S:267 E:270 ||| IN
cell  ||| S:270 E:275 ||| NN
cycle  ||| S:275 E:281 ||| NN
regulators  ||| S:281 E:292 ||| NNS
p16ink4a ||| S:292 E:300 ||| RB
,  ||| S:300 E:302 ||| ,
p21 ||| S:302 E:305 ||| NNP
,  ||| S:305 E:307 ||| ,
p27 ||| S:307 E:310 ||| NNP
,  ||| S:310 E:312 ||| ,
in  ||| S:312 E:315 ||| IN
association  ||| S:315 E:327 ||| NN
with  ||| S:327 E:332 ||| IN
proliferation  ||| S:332 E:346 ||| NN
and  ||| S:346 E:350 ||| CC
prognosis  ||| S:350 E:360 ||| JJ
factors  ||| S:360 E:368 ||| NNS
Ki-67 ||| S:368 E:373 ||| RB
,  ||| S:373 E:375 ||| ,
p53  ||| S:375 E:379 ||| NN
respectively ||| S:379 E:391 ||| RB
,  ||| S:391 E:393 ||| ,
in  ||| S:393 E:396 ||| IN
cell  ||| S:396 E:401 ||| NN
cultures ||| S:401 E:409 ||| NNS
,  ||| S:409 E:411 ||| ,
obtained  ||| S:411 E:420 ||| VBN
from  ||| S:420 E:425 ||| IN
different  ||| S:425 E:435 ||| JJ
types  ||| S:435 E:441 ||| NNS
of  ||| S:441 E:444 ||| IN
cervical  ||| S:444 E:453 ||| JJ
intra-epithelial  ||| S:453 E:470 ||| JJ
lesions ||| S:470 E:477 ||| NNS
.  ||| S:477 E:479 ||| .
The  ||| S:479 E:483 ||| DT
final  ||| S:483 E:489 ||| JJ
purpose  ||| S:489 E:497 ||| NN
was  ||| S:497 E:501 ||| VBD
to  ||| S:501 E:504 ||| TO
distinguish  ||| S:504 E:516 ||| VB
a  ||| S:516 E:518 ||| DT
best  ||| S:518 E:523 ||| RBS
marker  ||| S:523 E:530 ||| JJ
able  ||| S:530 E:535 ||| JJ
to  ||| S:535 E:538 ||| TO
identify  ||| S:538 E:547 ||| VB
with  ||| S:547 E:552 ||| IN
high  ||| S:552 E:557 ||| JJ
accuracy  ||| S:557 E:566 ||| NN
the  ||| S:566 E:570 ||| DT
high-grade  ||| S:570 E:581 ||| JJ
squamous  ||| S:581 E:590 ||| JJ
intra-epithelial  ||| S:590 E:607 ||| JJ
lesion ||| S:607 E:613 ||| NN
.  ||| S:613 E:615 ||| .
The  ||| S:615 E:619 ||| DT
study  ||| S:619 E:625 ||| NN
was  ||| S:625 E:629 ||| VBD
carried  ||| S:629 E:637 ||| VBN
out  ||| S:637 E:641 ||| RP
on  ||| S:641 E:644 ||| IN
68  ||| S:644 E:647 ||| CD
epithelial  ||| S:647 E:658 ||| JJ
cell  ||| S:658 E:663 ||| NN
cultures ||| S:663 E:671 ||| NNS
.  ||| S:671 E:673 ||| .
Three  ||| S:673 E:679 ||| CD
senior  ||| S:679 E:686 ||| JJ
specialists  ||| S:686 E:698 ||| NNS
have  ||| S:698 E:703 ||| VBP
analyzed  ||| S:703 E:712 ||| VBN
500  ||| S:712 E:716 ||| CD
cells ||| S:716 E:721 ||| NNS
/ ||| S:721 E:722 ||| JJ
case  ||| S:722 E:727 ||| NN
individually ||| S:727 E:739 ||| RB
.  ||| S:739 E:741 ||| .
The  ||| S:741 E:745 ||| DT
statistic  ||| S:745 E:755 ||| JJ
analysis  ||| S:755 E:764 ||| NN
for  ||| S:764 E:768 ||| IN
correlation  ||| S:768 E:780 ||| NN
between  ||| S:780 E:788 ||| IN
used  ||| S:788 E:793 ||| JJ
markers  ||| S:793 E:801 ||| NN
has  ||| S:801 E:805 ||| VBZ
been  ||| S:805 E:810 ||| VBN
performed ||| S:810 E:819 ||| VBN
.  ||| S:819 E:821 ||| .
The  ||| S:821 E:825 ||| DT
study  ||| S:825 E:831 ||| NN
batch  ||| S:831 E:837 ||| NN
revealed  ||| S:837 E:846 ||| VBD
a  ||| S:846 E:848 ||| DT
very  ||| S:848 E:853 ||| RB
low  ||| S:853 E:857 ||| JJ
expression  ||| S:857 E:868 ||| NN
of  ||| S:868 E:871 ||| IN
investigated  ||| S:871 E:884 ||| JJ
parameters  ||| S:884 E:895 ||| NNS
(  ||| S:895 E:896 ||| -LRB-
< ||| S:896 E:897 ||| SYM
1 ||| S:897 E:898 ||| CD
% ||| S:898 E:899 ||| NN
)  ||| S:899 E:901 ||| -RRB-
in  ||| S:901 E:904 ||| IN
negative  ||| S:904 E:913 ||| JJ
cases  ||| S:913 E:919 ||| NNS
for  ||| S:919 E:923 ||| IN
malignancy  ||| S:923 E:934 ||| NN
and  ||| S:934 E:938 ||| CC
intraepithelial  ||| S:938 E:954 ||| JJ
lesion  ||| S:954 E:961 ||| NNS
( ||| S:961 E:962 ||| -LRB-
NMIL ||| S:962 E:966 ||| NNP
) ||| S:966 E:967 ||| -RRB-
,  ||| S:967 E:969 ||| ,
a  ||| S:969 E:971 ||| DT
progressive  ||| S:971 E:983 ||| JJ
exponential  ||| S:983 E:995 ||| JJ
expression  ||| S:995 E:1006 ||| NN
in  ||| S:1006 E:1009 ||| IN
low-grade  ||| S:1009 E:1019 ||| JJ
squamous  ||| S:1019 E:1028 ||| FW
intraepithelial  ||| S:1028 E:1044 ||| FW
lesion  ||| S:1044 E:1051 ||| FW
( ||| S:1051 E:1052 ||| -LRB-
LSIL ||| S:1052 E:1056 ||| NNP
) ||| S:1056 E:1057 ||| -RRB-
,  ||| S:1057 E:1059 ||| ,
and  ||| S:1059 E:1063 ||| CC
a  ||| S:1063 E:1065 ||| DT
very  ||| S:1065 E:1070 ||| RB
high  ||| S:1070 E:1075 ||| JJ
expression  ||| S:1075 E:1086 ||| NN
in  ||| S:1086 E:1089 ||| IN
high-grade  ||| S:1089 E:1100 ||| JJ
squamous  ||| S:1100 E:1109 ||| JJ
intra-epithelial  ||| S:1109 E:1126 ||| JJ
lesion  ||| S:1126 E:1133 ||| NNS
( ||| S:1133 E:1134 ||| -LRB-
HSIL ||| S:1134 E:1138 ||| NNP
)  ||| S:1138 E:1140 ||| -RRB-
and  ||| S:1140 E:1144 ||| CC
invasive  ||| S:1144 E:1153 ||| FW
squamous  ||| S:1153 E:1162 ||| FW
cervical  ||| S:1162 E:1171 ||| FW
carcinoma  ||| S:1171 E:1181 ||| FW
( ||| S:1181 E:1182 ||| -LRB-
ISCC ||| S:1182 E:1186 ||| NNP
) ||| S:1186 E:1187 ||| -RRB-
.  ||| S:1187 E:1189 ||| .
Ki-67  ||| S:1189 E:1195 ||| NNP
and  ||| S:1195 E:1199 ||| CC
p53  ||| S:1199 E:1203 ||| NN
were  ||| S:1203 E:1208 ||| VBD
overexpressed  ||| S:1208 E:1222 ||| VBN
in  ||| S:1222 E:1225 ||| IN
nuclei  ||| S:1225 E:1232 ||| VBG
both  ||| S:1232 E:1237 ||| DT
in  ||| S:1237 E:1240 ||| IN
LSIL  ||| S:1240 E:1245 ||| NNP
and  ||| S:1245 E:1249 ||| CC
HSIL ||| S:1249 E:1253 ||| NNP
.  ||| S:1253 E:1255 ||| .
A  ||| S:1255 E:1257 ||| DT
slightly  ||| S:1257 E:1266 ||| RB
direct  ||| S:1266 E:1273 ||| JJ
correlation  ||| S:1273 E:1285 ||| NN
between  ||| S:1285 E:1293 ||| IN
p21  ||| S:1293 E:1297 ||| NNP
and  ||| S:1297 E:1301 ||| CC
Ki-67  ||| S:1301 E:1307 ||| NNP
( ||| S:1307 E:1308 ||| -LRB-
r=0.35 ||| S:1308 E:1314 ||| NNP
,  ||| S:1314 E:1316 ||| ,
p  ||| S:1316 E:1317 ||| CD
< ||| S:1317 E:1318 ||| SYM
0.001 ||| S:1318 E:1323 ||| CD
)  ||| S:1323 E:1325 ||| -RRB-
was  ||| S:1325 E:1329 ||| VBD
observed  ||| S:1329 E:1338 ||| VBN
in  ||| S:1338 E:1341 ||| IN
HSIL ||| S:1341 E:1345 ||| NNP
.  ||| S:1345 E:1347 ||| .
Statistically  ||| S:1347 E:1361 ||| RB
significant  ||| S:1361 E:1373 ||| JJ
correlations  ||| S:1373 E:1386 ||| NN
were  ||| S:1386 E:1391 ||| VBD
noticed  ||| S:1391 E:1399 ||| VBN
between  ||| S:1399 E:1407 ||| IN
some  ||| S:1407 E:1412 ||| DT
markers ||| S:1412 E:1419 ||| NN
:  ||| S:1419 E:1421 ||| :
p16ink4a  ||| S:1421 E:1430 ||| CD
and  ||| S:1430 E:1434 ||| CC
p27  ||| S:1434 E:1438 ||| NNP
( ||| S:1438 E:1439 ||| -LRB-
r=0.4 ||| S:1439 E:1444 ||| NNP
,  ||| S:1444 E:1446 ||| ,
p=0.03 ||| S:1446 E:1452 ||| CD
) ||| S:1452 E:1453 ||| -RRB-
,  ||| S:1453 E:1455 ||| ,
p16ink4a  ||| S:1455 E:1464 ||| NNP
and  ||| S:1464 E:1468 ||| CC
Ki-67  ||| S:1468 E:1474 ||| NNP
( ||| S:1474 E:1475 ||| -LRB-
r=-0.4 ||| S:1475 E:1481 ||| NNP
,  ||| S:1481 E:1483 ||| ,
p=0.002 ||| S:1483 E:1490 ||| CD
) ||| S:1490 E:1491 ||| -RRB-
.  ||| S:1491 E:1493 ||| .
The  ||| S:1493 E:1497 ||| DT
most  ||| S:1497 E:1502 ||| RBS
reliable  ||| S:1502 E:1511 ||| JJ
parameters  ||| S:1511 E:1522 ||| NNS
for  ||| S:1522 E:1526 ||| IN
assessing  ||| S:1526 E:1536 ||| VBG
HSIL  ||| S:1536 E:1541 ||| NNP
and  ||| S:1541 E:1545 ||| CC
ISCC  ||| S:1545 E:1550 ||| NNP
proved  ||| S:1550 E:1557 ||| VBD
to  ||| S:1557 E:1560 ||| TO
be  ||| S:1560 E:1563 ||| VB
Ki-67  ||| S:1563 E:1569 ||| NNP
and  ||| S:1569 E:1573 ||| CC
p16ink4a ||| S:1573 E:1581 ||| NNP
.  ||| S:1581 E:1583 ||| .
Both  ||| S:1583 E:1588 ||| DT
were  ||| S:1588 E:1593 ||| VBD
with  ||| S:1593 E:1598 ||| IN
percentages  ||| S:1598 E:1610 ||| NNS
and  ||| S:1610 E:1614 ||| CC
intensity  ||| S:1614 E:1624 ||| NN
of  ||| S:1624 E:1627 ||| IN
IFE  ||| S:1627 E:1631 ||| NNP
around  ||| S:1631 E:1638 ||| IN
100 ||| S:1638 E:1641 ||| CD
%  ||| S:1641 E:1643 ||| NN
and  ||| S:1643 E:1647 ||| CC
higher  ||| S:1647 E:1654 ||| JJR
immunoexpression  ||| S:1654 E:1671 ||| NN
within  ||| S:1671 E:1678 ||| IN
the  ||| S:1678 E:1682 ||| DT
nucleus  ||| S:1682 E:1690 ||| NN
of  ||| S:1690 E:1693 ||| IN
cell  ||| S:1693 E:1698 ||| NN
cultures ||| S:1698 E:1706 ||| NNS
.  ||| S:1706 E:1708 ||| .
Our  ||| S:1708 E:1712 ||| PRP$
study  ||| S:1712 E:1718 ||| NN
reveals  ||| S:1718 E:1726 ||| VBZ
that  ||| S:1726 E:1731 ||| IN
p27  ||| S:1731 E:1735 ||| CD
cyclin  ||| S:1735 E:1742 ||| CD
inhibitor  ||| S:1742 E:1752 ||| NNS
was  ||| S:1752 E:1756 ||| VBD
not  ||| S:1756 E:1760 ||| RB
reliable  ||| S:1760 E:1769 ||| JJ
in  ||| S:1769 E:1772 ||| IN
differentiating  ||| S:1772 E:1788 ||| VBG
between  ||| S:1788 E:1796 ||| IN
LSIL  ||| S:1796 E:1801 ||| NNP
and  ||| S:1801 E:1805 ||| CC
HSIL ||| S:1805 E:1809 ||| NNP
.  ||| S:1809 E:1811 ||| .
